Story · Medicine & Biotech

Kamel Abou Hussein: Important Milestone in the Evolving Treatment Landscape of HR+/HER2− MBC

1 outlet · first reported by OncoDaily on

Kamel Abou Hussein, Director of Breast Medical Oncology at MD Anderson Cancer Center at Cooper, shared on LinkedIn: “The FDA has approved giredestrant (Wilserdly) in combination with everolimus (Afinitor) for (OncoDaily)

Coverage, in order

  1. OncoDaily obscure
    Kamel Abou Hussein: Important Milestone in the Evolving Treatment Landscape of HR+/HER2− MBC

    Kamel Abou Hussein, Director of Breast Medical Oncology at MD Anderson Cancer Center at Cooper, shared on LinkedIn: “The FDA has approved giredestrant (Wilserdly) in combination with everolimus (Afinitor) for

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.